Nav: Home

Announcing the inaugural online immuno-oncology symposium

March 28, 2017

Oncology Central is delighted to be hosting, "Practical clinical aspects of immuno-oncology" a 2-day online symposium exploring the latest developments in cancer immunotherapy, chaired by Professor Angus Dalgleish (St George's, University of London).

Immunotherapy is a huge and still-emerging area within oncology, which is having a significant impact on the way patients with certain malignancies are being treated. This year, the American Society of Clinical Oncology (ASCO) named cancer immunotherapy as their clinical cancer Advance of the Year for a second consecutive year, highlighting its continuing importance in changing the face of cancer care.

At the end of June, Oncology Central is hosting a free 2-day online educational symposium, chaired by Professor Angus Dalgleish (St George's, University of London) delivering a series of talks and discussions by leading experts in the field, aiming to review the current status of immunotherapy in the clinic.

This event will be delivered on a highly interactive platform, and will offer delegates a unique opportunity to further explore recent trends and data in the field of cancer immunotherapy, as well as the opportunity to discuss and debate how these may impact everyday practice. Our experts will present on key areas such as rational combinations of immunotherapies with other therapies and management of therapy-related toxicities, as well as looking at optimization of these therapies and discussing the need for better biomarkers of response.

"As immunotherapy continues to make waves within oncology, we are excited to be able to offer this unique, fully online event in collaboration with some of the leading experts in the field," commented Jade Parker, Editor of Oncology Central. "Our encompassing programme aims to deliver a well-rounded update on the impact these therapies have had in the clinic thus far and to look to the future of the field."

Speakers already confirmed include Roy Herbst of Yale School of Medicine (CT, USA) and Hossein Borghaei of Fox Chase Cancer Center (PA, USA), with more to be announced soon.

This online symposium will be certified for CME credit. To find out more and to register for this free event, please click here: http://conferences.oncology-central.com/
-end-
About Oncology Central

Oncology is a fast-moving, multidisciplinary field at the forefront of medical research. At Oncology Central, the online resource powered by Future Science Group, we unite all aspects of oncology to support synergistic progression in the field through collaboration and learning.

Designed exclusively for medical professionals, and endorsed by an expanding board of expert Ambassadors from across the globe, we deliver high-quality and relevant content in an accessible and innovative way. Every day we aim to help you stay up to date with the latest developments in cancer research by providing the latest news, opinion, peer-reviewed journal articles, multimedia and exclusive content that can be digested quickly and easily.

Find out more: https://www.oncology-central.com

About Future Science Group

Founded in 2001, Future Science Group (FSG) is a progressive publisher focused on breakthrough medical, biotechnological, and scientific research. FSG's portfolio includes two imprints, Future Science and Future Medicine. In addition to this core publishing business, FSG develops specialist eCommunities. Key titles and sites include Bioanalysis Zone, Epigenomics, Nanomedicine and the award-winning Regenerative Medicine.

The aim of FSG is to service the advancement of clinical practice and drug research by enhancing the efficiency of communications among clinicians, researchers and decision-makers, and by providing innovative solutions to their information needs. This is achieved through a customer-centric approach, use of new technologies, products that deliver value-for-money and uncompromisingly high standards. http://www.futuresciencegroup.com

Future Science Group

Related Immunotherapy Articles:

Immunotherapy prior to surgery is effective in colon cancer
Patients with colon cancer, but no distant metastases, can benefit from a short course of immunotherapy while waiting for their surgery, as it can cause tumours to shrink substantially or clear up in a very short time.
Researchers discover potential boost to immunotherapy
Mount Sinai researchers have discovered a pathway that regulates special immune system cells in lung cancer tumors, suppressing them and allowing tumors to grow.
Predicting immunotherapy success
Weizmann Institute of Science researchers have now identified new markers that can help predict which patients have a better chance for a positive response to immunotherapy treatments.
Designer probiotic treatment for cancer immunotherapy
Columbia Engineers have engineered probiotics to safely deliver immunotherapies within tumors, including nanobodies against two proven therapeutic targets -- PD-L1 and CTLA-4.
Cancer vaccine could boost the effectiveness of immunotherapy
Supercharging the mutation rate in cancer cells can create a powerful vaccine that is able to boost the effectiveness of immunotherapy, a major new study reports.
Math models add up to improved cancer immunotherapy
A merger of math and medicine may help to improve the efficacy of immunotherapies, potentially life-saving treatments that enhance the ability of the patient's own immune system to attack cancerous tumors.
B cells linked to effective cancer immunotherapy
Cancer patients responded better to immunotherapy and had a better prognosis if their melanoma tumors contained specific clusters of B cells, according to new research from Lund University in Sweden.
B cells: New allies in sarcoma immunotherapy?
How can we improve and better personalize the treatment of soft tissue sarcomas, these particularly resistant and aggressive forms of cancer?
Transition to exhaustion: clues for cancer immunotherapy
Emory research on immune cells 'exhausted' by chronic viral infection provides clues on how to refine cancer immunotherapy.
Using artificial intelligence to determine whether immunotherapy is working
Currently, only about 20% of all cancer patients will actually benefit from costly immunotherapy.
More Immunotherapy News and Immunotherapy Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Climate Mindset
In the past few months, human beings have come together to fight a global threat. This hour, TED speakers explore how our response can be the catalyst to fight another global crisis: climate change. Guests include political strategist Tom Rivett-Carnac, diplomat Christiana Figueres, climate justice activist Xiye Bastida, and writer, illustrator, and artist Oliver Jeffers.
Now Playing: Science for the People

#562 Superbug to Bedside
By now we're all good and scared about antibiotic resistance, one of the many things coming to get us all. But there's good news, sort of. News antibiotics are coming out! How do they get tested? What does that kind of a trial look like and how does it happen? Host Bethany Brookeshire talks with Matt McCarthy, author of "Superbugs: The Race to Stop an Epidemic", about the ins and outs of testing a new antibiotic in the hospital.
Now Playing: Radiolab

Speedy Beet
There are few musical moments more well-worn than the first four notes of Beethoven's Fifth Symphony. But in this short, we find out that Beethoven might have made a last-ditch effort to keep his music from ever feeling familiar, to keep pushing his listeners to a kind of psychological limit. Big thanks to our Brooklyn Philharmonic musicians: Deborah Buck and Suzy Perelman on violin, Arash Amini on cello, and Ah Ling Neu on viola. And check out The First Four Notes, Matthew Guerrieri's book on Beethoven's Fifth. Support Radiolab today at Radiolab.org/donate.